secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0001493152-23-013037
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals files ANDA for generic antimetabolite; $42M market
------------------------------------------------------------------------

- Filed Abbreviated New Drug Application with FDA for an undisclosed generic antimetabolite drug.
- IQVIA reports annual sales of $42M for the generic market of this product (12 months ending Dec 2022).
- Elite is a specialty pharma developing niche generics; facility in Northvale, NJ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223013037/0001493152-23-013037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223013037/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-013037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer